Citadel Advisors
PRCT icon

Citadel Advisors’s Procept Biorobotics PRCT Stock Holding History

Citadel Advisors’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Buy
63,700
+10,200
+19% +$255K ﹤0.01% 7320
2026
Q1 		$1.34M Buy
53,500
+2,200
+4% +$62K ﹤0.01% 6987
2025
Q4 		$1.61M Buy
51,300
+4,700
+10% +$156K ﹤0.01% 6353
2025
Q3 		$1.66M Buy
46,600
+16,000
+52% +$731K ﹤0.01% 6450
2025
Q2 		$1.76M Sell
30,600
-7,500
-20% -$424K ﹤0.01% 5943
2025
Q1 		$2.22M Sell
38,100
-600
-2% -$41K ﹤0.01% 5334
2024
Q4 		$3.12M Sell
38,700
-300
-0.8% -$25.6K ﹤0.01% 4774
2024
Q3 		$3.12M Buy
39,000
+16,400
+73% +$1.17M ﹤0.01% 4704
2024
Q2 		$1.38M Sell
22,600
-40,900
-64% -$2.43M ﹤0.01% 6000
2024
Q1 		$3.14M Buy
63,500
+10,400
+20% +$495K ﹤0.01% 4700
2023
Q4 		$2.23M Buy
53,100
+19,300
+57% +$657K ﹤0.01% 5171
2023
Q3 		$1.11M Buy
33,800
+33,400
+8,350% +$1.14M ﹤0.01% 6350
2023
Q2 		$14.1K Sell
400
-2,400
-86% -$79.4K ﹤0.01% 13013
2023
Q1 		$79.5K Sell
2,800
-2,800
-50% -$98.8K ﹤0.01% 11563
2022
Q4 		$233K Sell
5,600
-64,800
-92% -$2.78M ﹤0.01% 9829
2022
Q3 		$2.92M Buy
70,400
+52,800
+300% +$2.11M ﹤0.01% 4857
2022
Q2 		$575K Buy
+17,600
New +$640K ﹤0.01% 8320

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors's PRCT Position: Q2 2026 in Review

Citadel Advisors opened a new position in Procept Biorobotics (PRCT) in Q2 2026: 12,612 shares worth $285K. The stake represents ﹤0.01% of the portfolio and ranks #11228 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in PRCT as recently as Q4 2025.

Citadel Advisors first reported a position in PRCT in Q3 2021 and has held it in 19 quarters since. The position peaked at $36.6M in Q3 2023. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Citadel Advisors held 12,612 shares of Procept Biorobotics worth $285K as of Q2 2026.
  • Procept Biorobotics was a new Citadel Advisors position in Q2 2026.
  • Procept Biorobotics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11228 holding.
  • Citadel Advisors first reported a position in Procept Biorobotics in Q3 2021 and has held it in 19 quarters since.
  • Citadel Advisors's Procept Biorobotics position peaked at $36.6M in Q3 2023.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.